First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study
This retrospective study examined real-world treatment patterns and outcomes in patients diagnosed with metastatic Merkel cell carcinoma (MCC) in England from 2013 to 2020. Among 667 patients identified, only 30% received systemic anticancer treatment, of whom 39% received first-line avelumab. Longer median overall survival was observed in patients treated with first-line avelumab vs. other first-line treatments, including patients with stage III MCC (37.8 vs. 13.0 months) or stage IV MCC (19.9 vs. 7.2 months).
Authors
- Patrice Verpillat (ORCID: https://orcid.org/0000-0003-0010-1699)
- Emmanuelle Boutmy (ORCID: https://orcid.org/0000-0001-9657-9376)
- Craig Knott (ORCID: https://orcid.org/0000-0002-8593-6216)
- Zoe Claire Venables (ORCID: https://orcid.org/0000-0002-9929-2693)
- Seyed Hamidreza Mahmoudpour (ORCID: https://orcid.org/0000-0001-5575-4238)
- Jenny Nobes (ORCID: https://orcid.org/0000-0002-0109-5983)
- Mairead Kearney
Institutions
- University of East Anglia (GB)
- Merck KGaA, Darmstadt (Germany) (DE)
- Norfolk and Norwich University Hospital (GB)
- Insight (China) (CN)
- NHS England
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1093/bjd/ljaf063
- Citations
- 2
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09